Supriya Lifescience Ltd is Rated Buy by MarketsMOJO
NiveshIQ
NSE: SUPRIYA · Healthcare
Supriya Lifescience Ltd.
₹859.60▲ ₹29.50 (+3.55%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SUPRIYA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Supriya Lifescience Ltd.
Supriya Lifescience Limited is a leading Indian pharmaceutical company engaged in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers a diverse portfolio of products across various therapeutic areas, including oncology, veterinary, and general categories. Its product offerings include GelHeal, a wound care solution, and Quickblue, an oral cancer detection kit. Supriya Lifescience Limited has a strong presence in the Indian market, with a revenue of ₹828 Cr and a net income of ₹209 Cr. The company is well-positioned to capitalize on the growing demand for pharmaceutical products in India and globally. With a strong research and development pipeline, Supriya Lifescience Limited is poised for growth and expansion in the
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹557.41 Cr +23.60% | ₹679.56 Cr +21.90% | ₹827.88 Cr +21.80% |
| EBITDA Margin | 33.23% | 39.64% | 36.91% |
| Net Profit | ₹119.11 Cr +32.60% | ₹187.96 Cr +57.80% | ₹209.12 Cr +11.30% |
| EPS | ₹14.80 | ₹23.35 | ₹25.98 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Supriya Lifescience opens postal ballot for Balasaheb Sawant re-appointment
Supriya Lifescience seeks approval to re-appoint Balasaheb Sawant as director
🔒
+ 3 more stories about Supriya Lifescience Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹277 Cr, PAT ₹74 Cr, EPS ₹9.22, EBITDA margin 36.6%. Growth context: revenue QoQ +34.0%, PAT QoQ +49.4%. Street verdict: inline, revenue surprise -1.4%, PAT surprise +4.3%.
Product pipeline delivery, domestic demand, export mix, approvals, and margin discipline will be crucial drivers for Sup...
FY26 (last completed FY): revenue ₹828 Cr, PAT ₹209 Cr, EBITDA margin 36.9%, EPS ₹25.98. Year-on-year: revenue YoY +21.8...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SUPRIYA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SUPRIYA alongside your other holdings
Unlock full SUPRIYA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Supriya Lifescience Ltd.?
NiveshIQ detects active intelligence signals for Supriya Lifescience Ltd. (SUPRIYA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Supriya Lifescience Ltd.?
Supriya Lifescience Ltd. operates in the Healthcare sector with a market capitalisation of ₹567,403.7L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.